Overview / Abstract: |
STATEMENT OF NEED Prostate cancer is the most common tumor type in men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with a dearth of effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 29,430 deaths annually. Median overall survival remains less than 2 years. TARGET AUDIENCE Medical oncologists, urologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment of patients with CRPC. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1. Assess predictive and prognostic markers to refine treatment planning for individual patients with CRPC |
Expiration |
Jan 14, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Monograph, Online |
Credits / Hours |
1.0 |
Accreditation |
ACCME; ANCC |
Presenters / Authors / Faculty |
Alicia K. Morgans, MD, MPH (Chairperson) Tanya Dorff, MD |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Sanofi Genzyme. |
Keywords / Search Terms |
i3 Health i3 Health, CRPC, prostate cancer, castration-resistant prostate cancer, urology, oncology, CME, CE, free CE, free CME, ILNA points Free CE CME |